North Carolina, USA-based biotech BioCryst Pharmaceuticals (Nasdaq: BCRX) on Friday announced it has signed a definitive agreement to sell its European Orladeyo (berotralstat) business to Italy’s Neopharmed Gentili for up to $264 million.
BioCryst, whose shares dipped more than 3% to $9.36 on the news, plans to use the proceeds from the transaction to retire all remaining term debt ($249 million) from Pharmakon, which will eliminate around $70 million of future interest payments. The company now expects to end 2027 with approximately $700 million in cash and no term debt. This represents an increase of $400 million to prior 2027 net cash guidance.
Orladeyo is marketed for the prevention of recurrent attacks of hereditary angioedema (HAE: rapid swelling under the skin). The drug generated net revenue in the first quarter of 2025 of $134.2 million (+51% year-over-year).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze